Inovio Pharmaceuticals (INO) closed at $1.46 on November 12, 2026, down 1.0% from the previous close, on volume of 7,485,862 shares (30-day average 18,878,211).
Data as of November 12, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 2, 2026 | Call Spread | 20-Nov-262 : 3 C | 3,174 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 12, 2026. See the 10 largest for 30, 60 and 90 days
INOVIO’s VOCERYQ Outlook Supports Reiterated Buy Rating and Unchanged $5 Price Target
TipRanks (Thu, 12-Nov 6:55 AM ET)
Inovio Earnings Call: VOCERYQ Launch Sets 2027 Path
TipRanks (Wed, 11-Nov 7:05 PM ET)
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks (Wed, 11-Nov 8:50 AM ET)
INOVIO to Participate in Upcoming Investor Conferences
PRNewswire (Wed, 11-Nov 8:05 AM ET)
Inovio Pharmaceuticals Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 10-Nov 5:35 PM ET)
Inovio Pharmaceuticals GAAP EPS of -$0.50 misses by $0.29
Seeking Alpha News (Tue, 10-Nov 4:09 PM ET)
INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights
PRNewswire (Tue, 10-Nov 4:05 PM ET)
Here are the major earnings after the close Tuesday
Seeking Alpha News (Tue, 10-Nov 10:00 AM ET)
These Are the Stocks Reporting Earnings Today – November 10, 2026
TipRanks (Tue, 10-Nov 4:30 AM ET)
Inovio Pharmaceuticals Underwriters Exercise Option for Additional Shares
TipRanks (Mon, 9-Nov 8:01 AM ET)
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Inovio Pharmaceuticals trades on the NASDAQ stock market under the symbol INO.
As of November 13, 2026, INO stock price declined to $1.44 with 3,144,405 million shares trading.
INO has a beta of 0.45, meaning it tends to be less sensitive to market movements. INO has a correlation of 0.00 to the broad based SPY ETF.
INO has a market cap of $258.69 million. This is considered a Small Cap stock.
Last quarter Inovio Pharmaceuticals reported $298,901 in Revenue and -$.50 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.30.
In the last 3 years, INO traded as high as $14.75 and as low as $.56.
The top ETF exchange traded funds that INO belongs to (by Net Assets): VTI, VXF, IWC, QQQS.
INO has underperformed the market in the last year with a return of -26.5%, while SPY returned +11.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in INO shares. However, INO has outperformed the market in the last 3 month and 2 week periods, returning +87.0% and +86.6%, while SPY returned -2.3% and -2.2%, respectively. This indicates INO has been having a stronger performance recently.
INO support price is $1.31 and resistance is $1.61 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INO shares will trade within this expected range on the day.
